24/7 Market News Snapshot 31 October, 2024 – Palisade Bio, Inc. Common Stock (NASDAQ:PALI)

October 31, 2024

DENVER, Colo., 31 October, 2024 (247marketnews.com) – (NASDAQ:PALI) are discussed in this article.
Palisade Bio, Inc. (PALI) is witnessing a significant surge in its stock value, currently trading at $3.860, which marks a remarkable 24.52% increase from the previous day’s close of $3.100. This notable rise, accompanied by a trading volume of 1.22 million shares, demonstrates heightened investor interest and optimism surrounding the company’s future prospects.

Driving this enthusiasm is Palisade Bio’s progressive research on PALI-2108, an innovative oral phosphodiesterase-4 (PDE4) inhibitor aimed at treating ulcerative colitis (UC). Recent findings from two translational studies, presented by Dr. Mitch Jones, Chief Medical Officer, at the American College of Gastroenterology’s 2024 Annual Scientific Meeting, underscore PALI-2108’s exceptional bioactivation capabilities. The research indicates that PALI-2108 is effectively converted into its active form, PALI-0008, within stool samples, achieving a remarkable 90.1% conversion rate within 24 hours.

Dr. Jones highlighted the importance of PALI-2108’s design, which aims to maximize efficacy while minimizing toxicity, particularly central nervous system side effects usually associated with existing PDE4 inhibitors. The active metabolite, PALI-0008, demonstrated a 20-fold increase in potency for inhibiting tumor necrosis factor-alpha (TNFα) production compared to current treatments, reinforcing its potential as a formidable therapeutic option for inflammatory bowel disease.

As Palisade Bio progresses towards a Phase 1 clinical study focused on the safety, tolerability, and pharmacokinetics of PALI-2108, the company is on track for patient dosing by year-end. This advancement could herald a new era of treatment for individuals suffering from autoimmune diseases, particularly UC, enhancing their quality of life with innovative and targeted therapy options.

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.